In the 10 years since Nature Reviews Endocrinology was first published, many important advances in the field of repro ductive endocrinology have occurred. During this decade, incredible advances have been made in science and medicine in general as a result of new tools (such as genetics, epi genetics and big data) that are available in dis covery research and can be applied to human biology and medicine. These advances have made the past decade an exciting time to be involved in transla tional research in repro ductive biology. As the many advances in this field over the past decade could not all be included in this article, I have limited the scope to advances involving, directly or indirectly, hormones, neuroendocrine factors and paracrine factors.
I will start at the top of the reproductive axis, with advances in our understanding of the neuroendocrine control of reproduction ( Figure 1 ). Hypothalamic gonadotropin releasing hormone (GnRH) is at the top of the axis and has effects in the pituitary gland, where peripheral and central signals are inte grated to control the output of gonado tropins, luteinizing hormone (LH) and folliclestimulating hormone (FSH). In turn, LH and FSH act on the gonads to stimu late gametogenesis and the production of gonadal sex steroids and peptides, includ ing estrogens, progesterone and testoster one, as well as inhibins. Although GnRH has his torically been considered to be at the apex of the reproductive axis, the past decade has led to important advances in our understand ing of upstream regulators of GnRH, heral ded by two key publications. 1, 2 Two groups independently reported the identification of mutations in GPR54 (now better known as KISS1R), which encodes a G proteincoupled receptor, in patients with hypogonadotropic hypogonadism, a dis order characterized by the absence of spon taneous pubertal matur ation, infertility and low levels of sex steroid hormones in associ ation with inappropriately lownormal levels of LH and FSH.
These two landmark papers reinvigorated the field of reproductive neuroendocrinol ogy. Subsequently, a multitude of studies in animal models, as well as in humans, determined that the ligand for this receptor, kisspeptin, is a potent stimulator of GnRH secretion, is produced in specific hypotha lamic neuronal populations and directly activates kisspeptin receptors in GnRH neurons. These findings confirm that kiss peptin is an upstream regulator of GnRH secretion. Four key roles of kisspeptin have been demonstrated by the >1,400 papers that have been published on this topic over the past decade. Firstly, the kisspeptin system is a gatekeeper of puberty and GnRH secretion. Secondly, kisspeptin is important for regulation of male and female fertil ity. Thirdly, kisspeptinsecreting neurons are important mediators of both negative and positive feedback of estrogen, thereby providing new insights into the regulation of ovulation and the menstrual or estrous cycle. Fourthly, kiss peptin is an important com ponent of the link between metabo lism and reproduction, as well as of other disruptors of reproductive control such as stress.
The identification of this new regulator of GnRH secretion using human genomics ushered in a new era of genetic discoveries in the control of puberty and reproduction, notably leading to the identification of loss offunction mutations in the genes encod ing neurokinin B (NKB) and its receptor, 3 This discovery took us further up the neuro nal ladder of GnRH control, with demonstrations that both NKB and NK3R are expressed in kisspeptin neurons and that this system regulates kiss peptin secretion to control GnRH release. These discoveries are already affecting clinical care, with intense pharmaceutical interest in the development of kisspeptin agonists and antagonists and a clinical study demonstrating the potential utility of kisspeptin to effectively and safely trigger oocyte maturation in women under going in vitro fertilization, with a possible reduction in the risk of ovarian hyperstim ulation syndrome. 4 In the past few years, the application of genomic tools to study patients with central precocious puberty (CPP; characterized by premature activa tion of GnRH secretion and early onset of puberty) has led to the identification of mutations in MKRN3 as a prevalent cause of CPP, confirming the genetic basis of this disorder and identifying the first inhib itor of GnRH secretion in humans. 5 This discovery has already had clinical implications in the diagnosis of CPP, enabling genetic counsel ling of family members and early treatment of this disorder. 5 These advances in our understanding of the neuroendocrine control of repro duction could improve the safety of fertil ity induction in patients at risk of ovarian hyperstimulation syndrome, such as those with polycystic ovary syndrome (PCOS). However, additional advances in the treat ment of these patients have also been made in the past decade. The historical mainstay of treatment for women with PCOS has been an estrogen-progestin contracep tive and clomi phene citrate when fertility is desired. PCOS is also associated with metabolic disturbances such as obesity and insulin resistance. Therapy with the insulin sensitizer, metfor min, ameliorates the meta bolic disturbances seen in PCOS; however, despite reports of improved ovulation rates, metformin did not increase the rate of live births. 6 Aromatase inhibitors (such as letro zole) have been pro posed as a method to induce ovulation in women with PCOS (Figure 1) . These drugs would also have stimulatory effects on the hypothalamicpituitary-gonadal axis and might be better than clomiphene citrate, providing more physiologic hormonal stimu lation of the endometrium, a lower rate of multiple pregnancies and a more favourable adverse effect profile. Indeed, a doubleblind, multi centre, randomized trial demonstrated superiority of letrozole over clomiphene citrate for fertility induction in women with PCOS. 7 Genes associated with PCOS, most notably DENND1A, have been identified in genomewide association studies and could open up opportunities for the development of additional targets for the treatment of this disorder (Figure 1 ). 8 The importance of antiMüllerian hor mone (AMH) in female reproduction has been revealed over the past decade. AMH was initially known as a 'male' hormone because of its role in male sexual differen tiation; it is produced in the testes and causes regression of the Müllerian ducts during male fetal sexual differentiation. AMH was subsequently shown to be produced in granu losa cells of the ovary and identified as an inhibitor of primordial follicle recruit ment. Now recognized as a biomarker of ovarian reserve, serum levels of AMH are being used in the clinic as reliable predic tors of responsiveness to fertility induction therapy, 9 of ovarian damage and effects on the ovarian reserve after chemotherapy or radiotherapy and of age at the start of meno pause. 10 Thus, AMH is now recognized as an important 'female' hormone that is crucial for maintaining the right tempo of folliculo genesis, and with important diagnostic implications that enable a personalized approach to fertility induction therapy.
As we reflect on the many advances in reproductive endocrinology that have occurred in the past decade, we likewise can look forward to the discoveries of the next decade; for example, the further develop ment and application of selective progester one receptor modulators, elucidation of the effects of endocrine disruptors on oogenesis and spermatogenesis and the translation of epigenetic discoveries into clinical care. It is with great anticipation and excitement that we can look ahead to the next wave of discoveries and advances to improve our understanding of the most fundamental of biologic processes-reproduction and the preservation of our species. 
